首页 | 本学科首页   官方微博 | 高级检索  
检索        


Aktueller Status von ECST-2
Authors:F Kennedy  RL Featherstone  Prof MM Brown
Institution:1. Department of Brain Repair and Rehabilitation, UCL Institute of Neurology, Box 6, The National Hospital for Neurology & Neurosurgery, Queen Square, WC1N 3BG, London, Vereinigtes K?nigreich
Abstract:

Background

Carotid endarterectomy (CEA) is a common procedure performed in patients who have suffered a stroke or transient ischaemic attack (TIA) to prevent a recurrent event. Clinical trials have provided evidence for the safety and efficacy of CEA in patients with recently symptomatic stenosis. Carotid artery stenting is an alternative to CEA. However, medical treatment has improved in the last 30 years and trials are ongoing to assess the use of modern medical treatment in selected patients with carotid disease as an alternative to revascularization.

Methods

We have reviewed the published results from clinical trials investigating the best treatment for symptomatic and asymptomatic carotid artery stenosis. In this review we discuss carotid endarterectomy, stenting and medical treatment. We have also included an update on the Second European Carotid Surgery Trial (ECST-2) which is an ongoing trial comparing revascularization to optimized medical therapy in patients with low to intermediate risk of recurrent stroke.

Results

The North American Symptomatic Carotid Endarterectomy Trial (NASCET) and the European Carotid Surgery Trial (ECST) both show that patients with high-risk symptomatic carotid stenosis benefit from CEA over medical treatment alone. However, it has been shown that surgery appeared to be harmful or at least not beneficial in patients included in the trials whose characteristics predicted a low risk of recurrent stroke. The Asymptomatic Carotid Surgery Trial (ACST) also showed a small benefit in treating asymptomatic patients with CEA over medical therapy. Several published trials have compared stenting with endarterectomy and although endarterectomy appears safer in the short term, both treatments have similar long-term outcomes; therefore stenting can be used as an alternative to CEA for selected patients.

Conclusion

CEA and stenting can both be offered to patients with recently symptomatic carotid stenosis to prevent recurrent stroke. We await the results of current trials investigating the role of modern medical therapy in selected patients with low to intermediate risk of recurrent stroke as an alternative to revascularization. The English full-text version of this article is available at SpringerLink (under “Supplemental”).
Keywords:
本文献已被 SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号